The Council for the Advancement of Diabetes Research and Education (CADRE) is a nonprofit organization committed to reducing the devastating complications of both type 1 and type 2 diabetes through achievement of tight metabolic control. To achieve this goal, CADRE provides health care professionals with scientific information and educational programs to enable them to manage and empower their patients with diabetes.
Effectively managing diabetes requires both day-to-day disease management and up-to-date information on new discoveries and evolving therapies. CADRE has developed a wide-range of diabetes-related programming and materials to help healthcare professionals stay on top of new information, including:
- The CADRE Handbook of Diabetes Management
- CADRE's Current Diabetes Practice, the official CADRE newsletter
- Diabetes slides for use in lecture programs or as self-education resources
- CADRE Symposia and other live continuing medical education diabetes programs
These CADRE diabetes programs support, highlight, and promote practical guidelines for patient education and management as well as cutting-edge research in diabetes pathophysiology and treatment by addressing such issues as:
- Epidemiology, etiology, and pathophysiology of both type 1 and type 2 diabetes
- Intensive therapeutic guidelines and management strategies to reduce complications of diabetes
- Patient education and self-management
- Treatment options for type 1 and type 2 diabetes
- Trends in diabetes research
CADRE receives funding for its educational activities from multiple sources, including Amylin Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly & Company, GlaxoSmithKline, LifeScan, Merck & Co., Novartis, Novo Nordisk, Nutrition 21, Pfizer Inc, Sankyo Pharma, and sanofi-aventis.
